Why r/Programming Is Cracking Down on AI-Generated LLM Content In recent months, the surge of AI-driven language models (LLMs) has ...

Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...

Tensions in the Strait of Hormuz are raising alarms about the stability of global pharmaceutical supply chains, with potential implications for the U.S. generic drug market, which relies heavily on ...

In the era of A.I. agents, many Silicon Valley programmers are now barely programming. Instead, what they’re doing is deeply, deeply weird. Credit...Illustration by Pablo Delcan and Danielle Del Plato ...

The Go team has approved generic methods, reversing a longstanding position in the language's FAQ. The proposal, from Go co-designer Robert Griesemer, now moves to implementation. A key issue – that ...

A new analysis has raised concerns about the Cigna Group’s drug pricing strategy, finding that one of its subsidiaries, Quallent Pharmaceuticals, often charges more for generic medications than ...

President Donald Trump’s top health advisers announced a push to cut health costs by bringing more cutting-edge generic drugs to market in a press conference on Wednesday. The Food and Drug ...

Oct 3 (Reuters) - The U.S. Food and Drug Administration said on Friday it has launched a new pilot program to speed up the review process for generic drugs that are tested and manufactured entirely in ...

Marion Bradley, 57, filling a prescription for one of her customers . She is the lead pharmacist and co-owner of Beacon Falls Pharmacy. Credit: Carl Jordan Castro / C-HIT.org India supplies nearly ...

With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...